Board of Directors

Michael F. Powell, Ph.D., Managing Director, Sofinnova Ventures

Michael F. Powell, Ph.D. has served as a member of Anesiva’s board of directors since December 2005. Since 1997, he has served as Managing Director of Sofinnova Ventures, a venture capital firm. From December 1990 to June 1997, he was a Group Leader at Genentech, Inc, and from September 1987 to December 1990 was Director of Product Development for Cytel Corporation, a biotechnology company. In 1993, Dr. Powell was honored as a Fellow by the American Association of Pharmaceutical Scientists. Dr. Powell is the author of nearly 100 publications and books, including a treatise on vaccine design. From March 2001 to December 2005, Dr. Powell served on the board of directors of AlgoRx Pharmaceuticals, Inc. Dr. Powell currently serves on the board of directors of Threshold Pharmaceuticals and Orexigen, both biotechnology companies, as well as several private biotechnology companies including DiObex, Trius, Anza Therapeutics and Ascenta. Dr. Powell received a Ph.D. in Chemistry from the University of Toronto in 1981 and was a postdoctoral fellow in Bio-Organic Chemistry at the University of California, Berkeley.